Clinical trial NCT04791280: Study of the Intestinal Microbiota of Patients With Systemic Sclerosis
Official title: Study of the Intestinal Microbiota of Patients With Systemic Sclerosis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Systemic Sclerosis
Keywords: Gut microbiota
Systemic sclerosis
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2021-03-10
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with systemic sclerosis treated in the Internal Medicine Department of Saint Antoine Hospital and patients who will be newly diagnosed within 2 years after the beginning of the biological collection.

Brief summary: The term gut microbiota describes the entire intestinal microbial communities. Studies have established the important role played by the gut microbiome in modulating vital functions of the healthy host. The physiological effects of the microbiota for the host are, for the most part, beneficial. In several pathologies, an imbalance in the composition of the microbiota has been demonstrated.

Systemic sclerosis is an autoimmune, disorder of the connective tissue, characterized by vascular lesions, immunological abnormalities, and fibrosis of skin and internal organs As in many inflammatory diseases, there are painful digestive manifestations in systemic scleroderma that affect up to 90% of patients. The exact pathophysiology of the digestive involvement in systemic sclerosis is uncertain. The digestive manifestations of systemic sclerosis are frequent and can affect the entire digestive system.

However, there are few studies of the intestinal microbiota in this disease, which seems to be part of the same continuum of diseases with abnormalities of innate immunity. By analogy with chronic inflammatory bowel diseases, particularly Crohn's disease, we have raised the question of the existence of dysbiosis during scleroderma which could lead to episodes of acute, severe and recurrent inflammation of the peritoneum under the influence of triggering factors. The long-term prospects would be to look for ways to prevent attacks or to treat them more rapidly and effectively by using therapeutic targets in the intestinal microbiota.

The study population will be seen in the usual care setting, identically to all patients with systemic sclerosis treated in the department.

In case of an inflammatory disease outbreak, and depending on its severity, the patient will be seen again in consultation or hospitalized. Appropriate complementary examinations (biology, imaging, endoscopy) will be carried out and the treatment adapted.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years old
* Patient with a confirmed diagnosis of systemic sclerosis according to international criteria, before or after the start date of this study.
* Non-opposition of the patient

Exclusion Criteria:

* Subject under guardianship, curatorship or safeguard of justice
* Subject with state medical aid (AME)
* Subject does not speak French
* Subject unable to answer questions or express himself/herself
* Taking antibiotics or a colonic preparation within 6 weeks prior to stool collection will be a temporary contraindication to stool collection. The patient may be included, other usual care samples may be taken, but the stool sample will be deferred and taken at a later date.

Primary outcomes:
measure: Prevalence of dysbiosis
timeFrame: Throughout the whole study, up to 6 months
Secondary outcomes:
measure: Microbiota composition and diversity assessed by 16s sequencing
timeFrame: Throughout the whole study, up to 6 months
measure: The fecal bacterial composition in comparison to different subtypes of systemic sclerosis and evolution during the time
timeFrame: Throughout the whole study, up to 6 months
measure: Microbiota correlation
timeFrame: Throughout the whole study, up to 6 months
Other outcomes:
Locations:
city: Paris
country: France
facility: Hopital Saint Antoine - service de médecine interne
Study officials:
affiliation: Assistance Publique - Hôpitaux de Paris
name: Arsène MEKINIAN, professor
role: PRINCIPAL_INVESTIGATOR
References: